Supplementary Files
Keywords
Hemophagocytic syndrome
Macrophage activation syndrome
Immune chaos
Abstract
Background: The hemophagocytic syndrome is a serious complication of several systemic illnesses.
Objective: To define the characteristics of the hemophagocytic syndrome at a pediatric specialty hospital in Tuxtla Gutiérrez, Chiapas, Mexico; incidences, underdiagnosis and overdiagnosis, associated conditions, treatment, and prognosis were included.
Methods: 214 cases of probable hemophagocytic syndrome that were seen between January 2011 and May 2019 were analyzed. 26 patients diagnosed with hemophagocytic syndrome and 188 cases with suspicion of this entity and/or ferritin > 500 ug/L were included. The cases that met four or more criteria of the HFS (Histiocyte Society, 2004) were included in this study.
Results: Thirty-five cases were validated (fourteen were previously diagnosed, nine had suspicion, and twelve had ferritin > 500 μg/L). Neither twelve out of 26 of the cases that were previously diagnosed (46.2 % overdiagnosed). Of the 35 validated cases, 21 hadn’t been diagnosed (60% underdiagnosed) met the diagnostic criteria of the HFS. The annual occurrence was of 2.0/1000 egresses. The Epstein-Barr virus was involved in 42% of the cases. The overall mortality was of 80%.
Conclusions: Hemophagocytic syndrome had been significantly underdiagnosed and overdiagnosed at the analyzed hospital. The clinical features allow early suspicion, diagnosis, and treatment. Specific and non-specific illnesses that were associated to hemophagocytic syndrome were identified.
References
Scott R, Robb-Smith A. Histiocytic medullary reticulosis. Lancet. 1939;234(6047):194-198. DOI: 10.1016/S0140-6736(00)61951-7
Malinowska I, Machaczka M, Popko K, Siwicka A, Salamonowicz M, Nasiłowska-Adamska B. Hemophagocytic syndrome in children and adults. Arch Immunol Ther Exp (Warsz). 2014;62(5):385-394. DOI: 10.1007/s00005-014-0274-1
Atteritano M, David A, Bagnato G, Beninati C, Frisina A, Iaria C, et al. Haemophagocytic syndrome in rheumatic patients. A systematic review. Eur Rev Med Pharmacol Sci. 2012;16(10):1414-1424.
Henter JI, Horne AC, Aricó M, Egeler M, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131. DOI: 10.1002/pbc.21039
Astigarraga I, González-Granado LI, Allende LM, Alsina L. Haemophagocytic syndromes: the importance of early diagnosis and treatment. An Pediatr (Barc). 2018;89(2):124.e1-124.e8. DOI: 10.1016/j.anpedi.2018.05.003
Xu XJ, Wang HS, Ju XL, Xiao PF, Xiao Y, Xue HM, et al. Clinical presentation and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in China: a retrospective multicenter study. Pediatr Blood Cancer. 2017;64(4). DOI: 10.1002/pbc.26264
Ishii E, Ohga S, Imashuku S, Yasukawa M, Tsuda H, Miura I, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol. 2007;86(1):58-65. DOI: 10.1532/IJH97.07012
Rajagopala S, Singh N. Diagnosing and treating hemophagocytic lymphohistiocytosis in the tropics: systematic review from the Indian subcontinent. Acta Med Acad. 2012;41(2):161-174. DOI: 10.5644/am2006-124.49
Verdugo P, Rodríguez N, Tordecilla J, Soto V. Síndrome hemofagocítico secundario en pediatría. Experiencia clínica en ocho casos. Rev Chil Pediatr. 2005;76(4):397-403.
Santidrian V, Rosso D, Elena G. Síndrome hemofagocítico en pediatría. Revisión bibliográfica. Rev Ped Elizalde. 2013;4(1):18-22. Disponible en: https://apelizalde.org/revistas/2013-1-ARTICULOS/RE_2013_1_RB_1.pdf
Sánchez IP, Leal-Esteban LC, Álvarez-Álvarez JA, Pérez-Romero CA, Orrego JC, Serna ML, et al. Analyses of the PRF1 gene in individuals with hemophagocytic lymphohystiocytosis reveal the common haplotype R54C/A91V in Colombian unrelated families associated with late onset disease. J Clin Immunol. 2012;32(4):670-680. DOI: 10.1007/s10875-012-9680-5
Espinosa-Bautista KA, Garciadiego-Fossas P, León-Rodríguez E. Síndrome hemofagocítico. Conceptos actuales. Gac Med Mex. 2013;149(4):431-437. Disponible en: https://www.medigraphic.com/pdfs/gaceta/gm-2013/gm134g.pdf
Gholam C, Grigoriadou S, Gilmour KC, Gaspar HB. Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management. Clin Exp Immunol. 2011;163(3):271-283. DOI: 10.1111/j.1365-2249.2010.04302.x
Goel S, Polski JM, Imran H. Sensitivity and specificity of bone marrow hemophagocytosis in hemophagocytic lymphohistiocytosis. Ann Clin Lab Sci. 2012;42(1):21-25. Disponible en: http://www.annclinlabsci.org/content/42/1/21.full.pdf+html
Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;50(6):1227-1235. DOI: 10.1002/pbc.21423
Marsh RA. Epstein-Barr virus and hemophagocytic lymphohistiocytosis. Front Immunol. 2018;8:1902. DOI: 10.3389/fimmu.2017.01902
Elazary AS, Wolf DG, Amir G, Avni B, Rund D, Yehuda DB, et al. Severe Epstein-Barr virus-associated hemophagocytic syndrome in six adult patients. J Clin Virol. 2007;40(2):156-159. DOI: 10.1016/j.jcv.2007.06.014
Tangye SG, Palendira U, Edwards ES. Human immunity against EBV-lessons from the clinic. J Exp Med. 2017;214(2):269-283. DOI: 10.1084/jem.20161846
Fox CP, Shannon-Lowe C, Gothard P, Kishore B, Neilson J, O’Connor N, Rowe M. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells. Clin Infect Dis. 2010;51(1):66-69. DOI: 10.1086/653424
Ukeba-Terashita Y, Saita Y, Ito Y, Kanegane H, Kimura H, Kobayashi I. Chronological changes in Epstein-Barr virus genome and subsets of peripheral mononuclear cells in a case of HLH. Open J Pediatr. 2011;1(3). DOI: 10.4236/ojped.2011.13008
Sekigawa I, Suzuki J, Nawata M, Ikeda K, Koike M, Iida N,et al. Hemophagocytosis in autoimmune disease. Clin Exp Rheumatol. 2001;19(3):333-338. DOI: 10.1097/DAD.0000000000000166
Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:119. DOI: 10.3389/fimmu.2019.00119
Janka GE. Hemophagocytic syndromes. Blood Rev. 2007;21(5):245-253. DOI: 10.1016/j.blre.2007.05.001
Canna SW, Behrens EM. Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes. Pediatr Clin North Am. 2012;59(2):329-344. DOI: 10.1016/j.pcl.2012.03.002
Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med. 2015;66:145-159. DOI: 10.1146/annurev-med-061813-012806
Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematology Am Soc Hematol Educ Program. 2013;2013:605-611. DOI: 10.1182/asheducation-2013.1.605
Oguz MM, Sahin G, Altinel Acoglu E, Polat E, Yucel H, Oztek Celebi FZ, et al. Secondary hemophagocytic lymphohistiocytosis in pediatric patients: a single center experience and factors that influenced patient prognosis. Pediatr Hematol Oncol. 2019;36(1):1-16. DOI: 10.1080/08880018.2019.1572253. Epub 2019 Mar 1
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2021 Revista Alergia México